GLENMARK PHARMACEUTICALS
Back to Income Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Revenue History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Net Sales | ₹11,583 Cr | ₹12,305 Cr | ₹10,944 Cr | ₹10,641 Cr | ₹9,865 Cr |
What is the latest Revenue of GLENMARK PHARMACEUTICALS ?
Year | Revenue |
---|---|
Mar2024 | ₹11,583 Cr |
Mar2023 | ₹12,305 Cr |
Mar2022 | ₹10,944 Cr |
Mar2021 | ₹10,641 Cr |
Mar2020 | ₹9,865 Cr |
How is Revenue of GLENMARK PHARMACEUTICALS Trending?
Years | Revenue | % Change | |
---|---|---|---|
Mar2024 | ₹11,583 Cr | -5.86 | |
Mar2023 | ₹12,305 Cr | 12.44 | |
Mar2022 | ₹10,944 Cr | 2.85 | |
Mar2021 | ₹10,641 Cr | 7.86 | |
Mar2020 | ₹9,865 Cr | - |
Compare Revenue of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹43,540.6 Cr | 1.5% | 17.6% | 54.5% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹424,706.0 Cr | 2.3% | 11.7% | 5.1% | Stock Analytics | |
DIVIS LABORATORIES | ₹152,946.0 Cr | -1.6% | 4% | 58.7% | Stock Analytics | |
CIPLA | ₹120,751.0 Cr | 0.8% | 6.2% | -2.9% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹109,988.0 Cr | 0.7% | 9.8% | 19.8% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹96,066.7 Cr | -1% | 2.8% | -8% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | 1.5% |
17.6% |
54.5% |
SENSEX | -1.3% |
4.2% |
3.6% |
You may also like the below Video Courses